Trial Profile

A Randomized, Placebo-Controlled, Double-Blind Six Month Study Followed by an Open-Label Extension Phase to Evaluate the Efficacy, Safety and Tolerability of MN-001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Aug 2025 Number of arms changed from 2 to 3. Experimental arms Open-Label MN-001 added to study protocol.
19 May 2021 Status changed from active, no longer recruiting to completed, as per results presented at the 117th International Conference of the American Thoracic Society.
19 May 2021 Results assessing safety, tolerability and efficacy of MN-001 in idiopathic pulmonary fibrosis, presented at the 117th International Conference of the American Thoracic Society.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com